Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthetic Biologics Appoints VP Corporate Development

Executive Summary

Synthetic Biologics Inc. has appointed Dr Isaac J. Bright vice president of corporate development. Bright brings over 15 years of transactional and operational experience to the clinical stage company, which focuses on developing therapeutics to protect the gut microbiome. Prior to joining Synthetic Biologics, Bright was a partner at US private equity investment practice Merieux Development, before which he was vice president, corporate development and diagnostics at QuantaLife Inc.

You may also be interested in...

Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Executives On The Move: CEOs Named At Evolve Biologics, Miragen Therapeutics, Receptor Life Sciences

Chief commercial officer appointed at Moderna.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts